G-207 is under clinical development by Treovir and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II drugs for Gliosarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the G-207 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
G-207 is under development for high-grade glioma in children, medulloblastoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid/rhabdoid tumor and germ cell tumor, supratentorial brain tumor, gliosarcoma, glioblastoma multiforme, giant cell glioblastoma, midline diffuse glioma and anaplastic astrocytoma. The drug candidate is administered by intracerebral and intratumor routes. G207 is a modified herpes simplex type 1 virus (HSV) that has been genetically engineered to replicate aggressively in cancer cells to kill them while sparing normal cells. The drug candidate is based on HSV technology (now known as adeno-associated virus-like particles technology).
It was also under development for recurrent glioblastoma multiforme.
Treovir is a healthcare company that develops and commercialises G207 for recurrent glioblastoma in children. The company is headquartered in Bala Cynwyd, Pennsylvania, the US.
For a complete picture of G-207’s drug-specific PTSR and LoA scores, buy the report here.